Research Article

Morphological, Immunocytochemical, and Biochemical Studies of Rat Costal Chondrocytes Exposed to IL-1β and TGF-β1

Xiaoli Li, Xiaoyong Ren, Sisi Li, Jianmin Liang, Xiaoyan Zhao, Ting Wang, and Zhenghui Wang

1Department of Dermatology, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710004, China
2Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710004, China
3Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Correspondence should be addressed to Zhenghui Wang; wangzhenghui77@xjtu.edu.cn

Received 16 March 2017; Revised 1 May 2017; Accepted 11 May 2017; Published 4 July 2017

Academic Editor: Antonio Gloria

Copyright © 2017 Xiaoli Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study was undertaken to determine the effects of IL-1β and TGF-β1 on the expression of differentiation-associated genes in chondrocytes in vitro. Rat costal chondrocytes were exposed to different concentrations of IL-1β and TGF-β1 for 48 h and tested for gene expression. IL-1β increased the expression of aggrecanase-1 and aggrecanase-2 and decreased the content of aggrecan and collagen II. Low concentration of TGF-β1 decreased the expression of aggrecan and collagen II and increased the expression of aggrecanase-2. However, the level of aggrecanase-1 was significantly elevated in the presence of high concentration of TGF-β1. IL-1β and TGF-β1 show the ability to modulate the production of aggrecan and collagen II in chondrocytes in vitro.

1. Introduction

Cartilage regeneration is often needed in orthopedic or plastic surgery for the repair of cartilaginous defects. However, due to the limited regenerative capacity of the cartilage tissue, the treatment of various cartilaginous lesions remains a challenge to clinicians. Recently, tissue engineering has emerged as a new method in which a combination of cells, scaffold, and bioactive agents is used to fabricate functional new tissue to replace damaged cartilage [1–3]. Chondrocytes seeded onto appropriate scaffolds can produce cartilage-like tissues, thus representing a major cell source for cartilage tissue engineering [4].

Once chondrocytes had been successfully cultured in vitro, study of cartilage matrix progressed rapidly. However, some issues remain unresolved, such as the dedifferentiation which occurs in cultured chondrocytes in vitro. As the number of passages increases, the cells undergo a change in phenotype and the morphology becomes more fibroblast-like [5]. Dedifferentiated chondrocytes lose their ability to form a matrix; they synthesize predominantly type-1 collagen. There is an associated downregulation of both aggrecan and type II collagen, the major protein produced by chondrocytes in cartilage [6, 7]. Thus, maintenance of the chondrocyte phenotype during a prolonged monolayer culture, delaying dedifferentiation, is crucial to chondrocyte transplantation and tissue engineering.

Many studies suggested that interleukin-1beta (IL-1β) and transforming growth factor beta 1 (TGF-β1) are implicated in cell differentiation [8, 9]. However, their roles in chondrocyte differentiation are not completely understood. In this study, we examined the effects of different concentrations of IL-1β and TGF-β1 on the production of collagen II, aggrecanase-1, aggrecanase-2, and aggrecan in chondrocytes, in order to explain the mechanism of IL-1β and TGF-β1 on chondrocyte differentiation.

2. Materials and Methods

2.1. Materials. Female Sprague-Dawley rats weighing about 120 g were purchased from the Laboratory Animal Center
of Xi’an Jiaotong University (Xi’an, China). DMEM and fetal bovine serum (FBS) were purchased from Invitrogen. Hyaluronidase, collagenase II, trypsin, and alcian blue 8GX (Sigma), mouse anti-rat collagen II monoclonal antibody (Neomarker), goat anti-rat aggrecan monoclonal antibody (Santa Cruz Biotechnology), DAB kit (Beijing Zhongshan), RNA isolation kit (Shanghai Feijie Company), and First Strand CDNA Synthesis Kit (MBI Fermentas) are the materials used.

2.2. Isolation and Culture of Chondrocytes. Isolation and culture of rat costal chondrocytes were performed as described previously [10]. In brief, rats were killed by cervical dislocation and the ribs were removed and the cartilage was

| Gene            | Primer sequences                        | Product size (bp) |
|-----------------|-----------------------------------------|------------------|
| β-actin         | Sense 5′-GAGGGAAATCGTGCGTGAC-3′         | 353              |
|                 | Antisense 5′-TAGGAGCCAGGGCAGTAATCT-3′  |                  |
| Aggrecanase-1   | Sense 5′-GCATCCGAACCCCTGTCAAC-3′       | 192              |
|                 | Antisense 5′-GGCGGTACGATCATAGTACC-3′   |                  |
| Aggrecanase-2   | Sense 5′-AACCTTGAATTGGGGCTGA-3′        | 290              |
|                 | Antisense 5′-CAATGGGGGATGGCAGACT-3′    |                  |
| Aggrecan        | Sense 5′-GCTACAGGGTGAAGCTTTGTACATCC-3′ | 478              |
|                 | Antisense 5′-GCTGTGCTCCCTCTAAATGTCAGATATCT-3′ |          |
| Collagen II     | Sense 5′-TGTTGCTGCTGCTGCTGCTGCAAAGCACCTCC-3′ | 339          |
|                 | Antisense 5′-GCCCTCTGATCAAAATCCTCAGCCATCTGGCCG-3′ |          |

Figure 1: Effects of different concentrations of IL-1β on the expression of aggrecan in chondrocytes. Representative immunocytochemical images are shown. ((a) Control; (b) 1 ng/ml; (c) 10 ng/ml; (d) 100 ng/ml). Bar = 50 μm.
collected and cut into 1 mm³ pieces. The tissue samples were digested with hyaluronidase and collagenase II, and the isolated cells were cultured at 37°C under a humidified atmosphere of 5% CO₂. Cells were subcultured at a ratio of 1:1 after treatment with 0.25% trypsin/EDTA. The isolated chondrocytes were identified by immunostaining for collagen II and aggrecan. In this study, cells at passage 2 were used.

2.3. Treatment of Chondrocytes with IL-1β and TGF-β1. Cells (5 × 10⁴) were seeded in triplicates onto 24-well plates and incubated with different concentrations of IL-1β or TGF-β1 (1, 10, and 100 ng/ml) for 48 h. The cells were then collected and tested for gene expression.

2.4. Immunocytochemical Analysis. Cells were plated on cover slips and allowed to grow to 80% confluence. Cells were washed and fixed with 4% paraformaldehyde for 30 min. Normal goat serum was used to block nonspecific binding sites. The coverslips were then incubated at 4°C overnight with antiaggrecan (1:200) and anticollagen II (1:200) antibody, followed by incubation with biotinylated IgG (1:400). The bound antibody was visualized using 3,3′-diaminobenzidine. The coverslips were mounted and examined under a microscope [11].

2.5. Semiquantitative Reverse Transcription-PCR (RT-PCR) Analysis. Total RNA was extracted from cells using TRIzol reagent (Shanghai Feijie Company, Shanghai, China). cDNA was reverse transcribed from total RNA using the First Strand cDNA Synthesis Kit (MBI Fermentas, Vilnius, Lithuania). PCR amplification was performed using the specific primers summarized in Table 1. PCR products were subjected to 1.5% agarose gel electrophoresis and stained with ethidium bromide. The bands were quantified by densitometry.

2.6. Statistical Analysis. Data are expressed as mean ± standard deviation. Differences among multiple groups were determined using one-way analysis of variance followed by Tukey’s post hoc test. A value of \( P < 0.05 \) indicated statistical significance.

3. Results

3.1. Morphological Findings. The isolated cells attached to the culture plate within 24 h and showed a typical polygon shape. After culturing for 3–5 days, cells grew to confluence and could be subcultured.

3.2. Immunocytochemical Studies. The amounts of aggrecan (Figure 1) and collagen II (Figure 2) were decreased with the increase in the concentration of IL-1β used. In contrast, treatment with high concentrations of TGF-β1 led to an increase in the aggrecan level (Figure 3) and decrease in the level of collagen II (Figure 4).

3.3. RT-PCR Analysis. Increased concentrations of IL-1β were associated with significantly (\( P < 0.05 \)) lower levels of aggrecan and collagen II transcripts, compared to the control group (Figure 5(a)). IL-1β at the concentration of 10 ng/ml
Figure 3: Effects of different concentrations of TGF-β1 on the expression of aggrecan in chondrocytes. Representative immunocytochemical images are shown. ((a) Control; (b) 1 ng/ml; (c) 10 ng/ml; (d) 100 ng/ml). Bar = 50 μm.

Figure 4: Effects of different concentrations of TGF-β1 on the expression of collagen II in chondrocytes. Representative immunocytochemical images are shown. ((a) Control; (b) 1 ng/ml; (c) 10 ng/ml; (d) 100 ng/ml). Bar = 50 μm.
resulted in a maximal induction of aggrecanase-1 and aggrecanase-2 in chondrocytes. The aggrecan amounts increased after treatment with 1 and 10 ng/ml TGF-$\beta$ but showed no significant change after treatment with 100 ng/ml TGF-$\beta$ (Figure 5(b)). TGF-$\beta$ treatment, especially at the concentration of 1 ng/ml, significantly induced the expression of aggrecanase-2. However, the level of aggrecanase-1 was significantly raised by the treatment with 100 ng/ml TGF-$\beta$. Additionally, the collagen II level was not significant difference with different concentration of TGF-$\beta$.

4. Discussion

Aggrecan and collagens are abundantly present in the extracellular matrix (ECM) of cartilaginous tissues [12]. Aggrecan is a proteoglycan that plays a critical role in chondrocyte growth and differentiation [13]. Aggrecanase-1 and/or aggrecanase-2 is the enzymes responsible for aggrecan cleavage during cytokine-induced cartilage degradation [14–16]. Aggrecanases have the ability to cleave aggrecan and are thus implicated in modulation of the behaviors of chondrocytes [17, 18]. Besides structural components, a number of growth factors such as IL-1$\beta$, TGF-$\beta$, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF) are also detected in cartilage ECM. These growth factors affect multiple aspects of chondrocyte biology including cell proliferation, metabolism, and survival [19, 20]. IL-1$\beta$ can suppress the proliferation of chondrocytes [21], while BMP and FGF are known to enhance chondrocyte growth [22]. However, the roles of TGF-$\beta$ in chondrocytes remain controversial. It has been documented that TGF-$\beta$ can facilitate protein synthesis and articular chondrocyte proliferation [23, 24], thus participating in the metabolism of cartilage ECM. De Haart et al. [25] reported that TGF-$\beta$1 is capable of stimulating the proliferation of primary chondrocytes but has a modest impact on the proliferation of chondrocytes after subculturing for several passages.

IL-1, consisting of two molecules (IL-1$\alpha$ and IL-1$\beta$), is primarily produced by mononuclear cells. IL-1$\beta$ is an important component of cartilage ECM [26] and plays a negative role in chondrocyte proliferation [23]. Our data showed that IL-1$\beta$ treatment significantly raised the amounts of aggrecanase-1 and aggrecanase-2 but decreased the production of aggrecan and collagen in chondrocytes. These results suggest that IL-1$\beta$ can induce the expression of aggrecanases
in chondrocytes and lead to ECM degradation, which in turn decreases the amount of collagen, consequently contributing to chondrocyte dedifferentiation. Our observations are consistent with a previous study [27].

Mature TGF-β (25 kDa in size), which is composed of two polypeptides linked with disulfide bonds, is a multifunctional cytokine. It plays a complex role in chondrocyte biology. It has been reported that TGF-β1 can stimulate protein synthesis and chondrocyte proliferation [26]. Similarly, Lee et al. [28] showed that TGF-β1-containing chitosan scaffolds provide proliferative advantages to chondrocytes, compared to control scaffolds. Shuler et al. [29] revealed that adenoviral delivery of TGF-β1 gene into chondrocytes led to a marked increase in collagen synthesis. However, TGF-β1 failed to rescue the collagen phenotype of dedifferentiated chondrocytes. Administration of high dose of TGF-β1 to damaged articular cartilage promoted tissue fibrosis [30]. In this study, we found that the collagen II level was reduced to the maximal extent after treatment with a moderate concentration of TGF-β1 (i.e., 10 ng/ml). In contrast, low to moderate concentrations of TGF-β1 decreased the expression of aggrecanase-1, while high concentration of TGF-β1 elevated the expression of aggrecanase-1 and aggrecanase-2. These results support the notion that TGF-β1 plays a dual role in chondrocyte differentiation [31].

Dedifferentiation is a major obstacle for chondrocyte-based tissue engineering. Both IL-1β and TGF-β1 can modulate the expression of aggrecan, collagen II, aggrecanase-1, and aggrecanase-2 in chondrocytes and thus have the potential to maintain chondrocyte phenotypes after serial passages.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (81670917, 81000416); Fundamental Research Funds for the Central Universities; Funds for the Second Affiliated Hospital of Xi’an Jiaotong University; and Funds for Shaanxi Province Ke Ji Gong Guan (2015SF169, 2016SF-073).

References
[1] Y. Jiang, Y. Cai, W. Zhang et al., "Human cartilage-derived progenitor cells from committed chondrocytes for efficient cartilage repair and regeneration," Stem Cells Translational Medicine, vol. 5, no. 6, pp. 733–744, 2016.
[2] N. Luciani, V. Du, F. Gazeau et al., "Successful chondrogenesis within scaffolds, using magnetic stem cell confinement and bioreactor maturation," Acta Biomaterialia, vol. 37, pp. 101–110, 2016.
[3] L. A. Solchaga, V. M. Goldberg, and A. I. Caplan, "Cartilage regeneration using principles of tissue engineering," Clinical Orthopaedics, vol. 391S, pp. 161–170, 2001.
[4] R. H. Das, H. Jahr, J. A. Verhaar, J. C. van der Linden, G. J. van Osch, and H. Weinans, "In vitro expansion affects the response of chondrocytes to mechanical stimulation," Osteoarthritis and Cartilage, vol. 16, no. 3, pp. 385–391, 2008.
[5] Z. H. Wang, X. L. Li, X. J. He et al., "Delivery of the Sox9 gene promotes chondrogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells in an in vitro model," Brazilian Journal of Medical and Biological Research, vol. 47, no. 4, pp. 279–286, 2014.
[6] Z. H. Wang, G. G. Li, Z. Q. Yang, L. Wang, L. X. Li, and X. J. He, "Culture of rat costochondral chondrocytes and effect of aging on matrix catabolism of cultured chondrocytes," Journal of Tissue Engineering in Reconstructive Surgery, vol. 5, pp. 312–316, 2007, in Chinese.
[7] D. G. Stokes, G. Liu, I. B. Coimbra, S. Piera-Velazquez, R. M. Crowl, and S. A. Jimenez, "Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis," Arthritis and Rheumatism, vol. 46, pp. 404–419, 2002.
[8] K. Kawamura, C. R. Chu, S. Sobajima et al., "Adenoviral-mediated transfer of TGF-beta1 but not IGF-1 induces chondrogenic differentiation of human mesenchymal stem cells in pellet cultures," Experimental Hematology, vol. 33, no. 8, pp. 865–872, 2005.
[9] J. E. Huh, P. S. Koh, B. K. Seo et al., "Mangiferin reduces the inhibition of chondrogenic differentiation by IL-1β in mesenchymal stem cells from subchondral bone and targets multiple aspects of the Smad and SOX9 pathways," International Journal of Molecular Sciences, vol. 15, no. 9, pp. 16025–16042, 2014.
[10] Z. H. Wang, Z. Q. Yang, X. J. He, L. Wang, L. X. Li, and J. B. Tu, "Effects of RNAi-mediated inhibition of aggrecanase-1 and aggrecanase-2 on rat costochondral chondrocytes in vitro," Acta Pharmacologica Sinica, vol. 29, no. 10, pp. 1215–1226, 2008.
[11] Z. H. Wang, X. L. Li, X. J. He, X. H. Zhang, and Z. Q. Yang, "Experimental study of tissue-engineered cartilage allograft with RNAi chondrocytes in vivo," Therapeutics and Clinical Risk Management, vol. 10, pp. 335–340, 2014.
[12] H. Akkiraju and A. Nohe, "Role of Chondrocytes in Cartilage Formation, Progression of Osteoarthritis and Cartilage Regeneration," Journal of Developmental Biology, vol. 3, no. 4, pp. 177–192, 2015.
[13] H. M. Ismail, K. Yamamoto, T. L. Vincent, H. Nagase, L. Troeberg, and J. Saklatvala, "Interleukin-1 acts via the JNK-2 signaling pathway to induce aggrecan degradation by human chondrocytes," Arthritis & Rheumatology, vol. 67, no. 7, pp. 1826–1836, 2015.
[14] J. D. Sandy, C. R. Flannery, P. J. Neame, and L. S. Lohmander, "The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-ala 374 bond of the interglobular domain," The Journal of Clinical Investigation, vol. 89, pp. 1512–1516, 1992.
[15] M. D. Tortorella, A. M. Malfait, C. Deccico, and E. Arner, "The role of ADAMTS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation," Osteoarthritis and Cartilage, vol. 9, pp. 539–552, 2001.
[16] E. C. Arner, M. A. Pratta, C. P. Decicco, C. B. Xue, R. C. Newton, and J. M. Trzaskos, "Aggrecanase: a target for the design of inhibitors of cartilage degradation," Annals of the New York Academy of Sciences, vol. 30, pp. 92–107, 1999.
[17] M. Chijiwa, S. Mochizuki, T. Kiumura et al., "CCN1 (Cyr61) is overexpressed in human osteoarthritic cartilage and inhibits
ADAMTS-4 (aggrecanase 1) activity,” *Arthritis & Rheumatology*, vol. 67, no. 6, pp. 1557–1567, 2015.

[18] M. A. Pratta, M. D. Tortorella, and E. C. Arner, “Age related changes in aggrecan glycosylation affect cleavage by aggrecanase,” *The Journal of Biological Chemistry*, vol. 275, pp. 39096–39102, 2000.

[19] S. Shi, J. Xie, J. Zhong et al., “Effects of low oxygen tension on gene profile of soluble growth factors in co-cultured adipose-derived stromal cells and chondrocytes,” *Cell Proliferation*, vol. 49, no. 3, pp. 341–351, 2016.

[20] G. Homandberg, “Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments,” *Frontiers in Bioscience*, vol. 15, pp. D713–D730, 1999.

[21] X. Li, Z. Zhen, G. Tang, C. Zheng, and G. Yang, “MiR-29a and MiR-140 protect chondrocytes against the anti-proliferation and cell matrix signaling changes by IL-1β,” *Molecules and Cells*, vol. 39, no. 2, pp. 103–110, 2016.

[22] M. Pei, L. Solchaga, J. Seidel et al., “Bioreactors mediate the effectiveness of tissue engineering scaffolds,” *The FASEB Journal*, vol. 16, no. 12, pp. 1691–1694, 2002.

[23] A. Denuziere, D. Ferrier, O. Damour, and A. Domard, “Chitosan-chondroitin sulfate and chitosan-hyaluronate polyelectrolyte complexes: biological properties,” *Biomaterials*, vol. 19, no. 14, pp. 1275–1285, 1998.

[24] T. I. Morales, “The role and content of endogenous insulin-like growth factor-binding proteins in bovine articular cartilage,” *Arhives of Biochemistry and Biophysics*, vol. 343, pp. 164–172, 1997.

[25] M. De Haart, W. J. Marijnissen, G. J. van Osch, and J. A. Verhaar, “Optimization of chondrocyte expansion in culture. Effect of TGF beta-2, bFGF and L-ascorbic acid on bovine articular chondrocytes,” *Acta Orthopaedica Scandinavica*, vol. 70, no. 1, pp. 55–61, 1999.

[26] J. P. Pelletier, R. McCollum, J. M. Cloutier, and J. Martel-Pelletier, “Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process,” *The Journal of Rheumatology. Supplement*, vol. 43, pp. 109–114, 1995.

[27] P. Mathieu, “Interieukin-1:its role, its dosage, the siffficulties in advance in arthritis. Results of a “pilot” study with diacerheine (ART 50) in gonarthrosis,” *La Revue du Praticien*, Supplement 13, pp. S15–S18, 1999.

[28] J. E. Lee, S. E. Kim, I. C. Kwon et al., “Effects of a chitosan scaffold containing TGF-β1 encapsulated chitosan microspheres on in vitro chondrocyte culture,” *Artificial Organs*, vol. 28, no. 9, pp. 829–839, 2004.

[29] F. D. Shuler, H. I. Georgescu, C. Niyibizi et al., “Increased matrix synthesis following adeno viral transfer of a transforming growth factor beta1 gene into articular chondrocytes,” *Journal of Orthopaedic Research*, vol. 18, no. 4, pp. 585–592, 2000.

[30] A. Hulth, O. Johnell, K. Miyazono, L. Lindberg, D. Heinegård, and C. H. Heldin, “Effect of transforming growth factor-beta and platelet-derived growth factor-BB on articular cartilage in rats,” *Journal of Orthopaedic Research*, vol. 14, pp. 547–553, 1996.

[31] K. Boumediene, D. Vivien, M. Macro, P. Bogdanowicz, E. Lebrun, and J. P. Pujol, “Modulation of rabbit articular chondrocyte (RAC) proliferation by TGF-beta isoforms,” *Cell Proliferation*, vol. 28, pp. 221–234, 1995.